TIL-Driven De-escalated Chemotherapy in Stage I-II TNBC
Recruiting
Phase 2
Interventional Study
Breast Cancer
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Trial phase
- Phase 2
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 40 (estimated)
- Sponsor
- D'Or Institute for Research and Education · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This is a phase II clinical study testing a more personalized and lighter chemotherapy approach for women with stage I or II triple-negative breast cancer. The treatment is adjusted based on signs from the immune system (called tumor-infiltrating lymphocytes, or TILs) and imaging results during treatment.
Patients with stage I triple-negative breast cancer (regardless of TIL levels) and those wit…
Trial Locations
Sorted by distance from Utah
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Histologically confirmed primary invasive breast carcinoma.
* One of the following conditions:
* Clinical stage T1c N0 M0 with any level of TILs; or
* Clinical stage T2 N0 M0 with TILs ≥ 50%.
* Estrogen receptor (ER) and progesterone receptor (PR) expression \< 10%.
* HER2-neg…
Contacts
Intituto D'Or de Pesquisa e Ensino São Paulo
pesquisaclinica@idor.org
CONTACT